| scholarly article | Q13442814 |
| P50 | author | Steven Rosenberg | Q2347448 |
| Yong-Chen Lu | Q42199992 | ||
| P2093 | author name string | Satyajit Ray | |
| Paul F Robbins | |||
| Peter C Fitzgerald | |||
| Yong F Li | |||
| Zhili Zheng | |||
| Jared J Gartner | |||
| Todd D Prickett | |||
| Eric Tran | |||
| Valery Bliskovsky | |||
| Zulmarie Franco | |||
| P2860 | cites work | High-throughput pairing of T cell receptor α and β sequences | Q85935018 |
| Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy | Q24596055 | ||
| Cancer regression in patients after transfer of genetically engineered lymphocytes | Q24654976 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
| T-cell antigen receptor genes and T-cell recognition | Q29619721 | ||
| Genetic basis for clinical response to CTLA-4 blockade in melanoma | Q29620594 | ||
| Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells | Q30621114 | ||
| T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. | Q30832820 | ||
| Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. | Q33851742 | ||
| Adoptive cell transfer as personalized immunotherapy for human cancer | Q34043643 | ||
| IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains | Q34164031 | ||
| IMGT®, the international ImMunoGeneTics information system® 25 years on. | Q34446760 | ||
| Design and Analysis of Single-Cell Sequencing Experiments | Q34500857 | ||
| T cell fate and clonality inference from single-cell transcriptomes | Q34517214 | ||
| Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. | Q34729631 | ||
| High-throughput identification of antigen-specific TCRs by TCR gene capture | Q35016476 | ||
| Linking T-cell receptor sequence to functional phenotype at the single-cell level | Q35111823 | ||
| The many important facets of T-cell repertoire diversity | Q35709655 | ||
| Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities | Q35850673 | ||
| Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. | Q36286122 | ||
| Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability | Q36286127 | ||
| Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients | Q36551911 | ||
| Cancer immunotherapy targeting neoantigens | Q36889067 | ||
| Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy | Q37107516 | ||
| Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes | Q37113080 | ||
| Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression | Q37197945 | ||
| Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma | Q37222679 | ||
| Genomic correlates of response to CTLA-4 blockade in metastatic melanoma | Q37319470 | ||
| Using bioinformatics tools for the sequence analysis of immunoglobulins and T cell receptors | Q38513969 | ||
| An immunogenic personal neoantigen vaccine for patients with melanoma | Q38692859 | ||
| Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients | Q38792012 | ||
| Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression. | Q38797183 | ||
| Immunogenicity of somatic mutations in human gastrointestinal cancers. | Q38823554 | ||
| 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. | Q39136403 | ||
| Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel | Q39249589 | ||
| Incorporation of transmembrane hydrophobic mutations in the TCR enhance its surface expression and T cell functional avidity. | Q39356556 | ||
| Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells | Q41916556 | ||
| A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days | Q42244370 | ||
| Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab | Q45070125 | ||
| Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy | Q45858516 | ||
| Mechanisms regulating T-cell infiltration and activity in solid tumors | Q50089395 | ||
| Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. | Q50906889 | ||
| Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer | Q57152489 | ||
| Expression of two T cell receptor alpha chains: dual receptor T cells | Q61268447 | ||
| 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function | Q78057869 | ||
| P433 | issue | 2 | |
| P921 | main subject | RNA sequencing | Q2542347 |
| single-cell RNA-seq | Q18409577 | ||
| P304 | page(s) | 379-389 | |
| P577 | publication date | 2017-10-28 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors | |
| P478 | volume | 26 |
| Q92963159 | Best practices for bioinformatic characterization of neoantigens for clinical utility |
| Q93167902 | CAR T cell therapy: newer approaches to counter resistance and cost |
| Q90576547 | Developing neoantigen-targeted T cell-based treatments for solid tumors |
| Q55011828 | Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells. |
| Q57029270 | Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy |
| Q64884539 | Functional genomics: paving the way for more successful cancer immunotherapy. |
| Q92509274 | Identification of drug-specific public TCR driving severe cutaneous adverse reactions |
| Q89456690 | Next-generation sequencing technologies accelerate advances in T-cell therapy for cancer |
| Q93104450 | Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy |
Search more.